Fortrea Holdings (FTRE) Cash & Current Investments (2022 - 2026)
Fortrea Holdings (FTRE) posted Cash & Current Investments of $147.5 million for Q1 2026, down 15.52% on a QoQ basis from $174.6 million in Q4 2025, and up 45.18% year-over-year from $101.6 million in Q1 2025.
Fortrea Holdings (FTRE) Cash & Current Investments (2022 - 2026) Analysis & Trends
Fortrea Holdings' Cash & Current Investments history runs 5 years deep, the most recent figure standing at $147.5 million for Q1 2026.
- Quarterly Cash & Current Investments rose 45.18% year-over-year to $147.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $147.5 million (up 45.18% YoY) and the FY2025 annual result came in at $174.6 million, up 47.34% from the prior year.
- Cash & Current Investments was $147.5 million for Q1 2026 at Fortrea Holdings, down from $174.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $174.6 million in Q4 2025 and bottomed at $81.2 million in Q2 2025.
- A 5-year average of $117.0 million and a median of $112.0 million in 2022 frame the typical range for Cash & Current Investments.
- Peak annual rise in Cash & Current Investments reached 47.34% in 2025, while the deepest fall reached 35.66% in 2025.
- Fortrea Holdings' Cash & Current Investments stood at $112.0 million in 2022, then declined by 3.04% to $108.6 million in 2023, then grew by 9.12% to $118.5 million in 2024, then soared by 47.34% to $174.6 million in 2025, then dropped by 15.52% to $147.5 million in 2026.
- Business Quant data shows FTRE's Cash & Current Investments at $147.5 million in Q1 2026, $174.6 million in Q4 2025, and $131.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Fortrea Holdings | 1.81 Bn | 1.67 Bn | 123.60 Mn | 147.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147.50 Mn |
| Dec 31, 2025 | 174.60 Mn |
| Sep 30, 2025 | 131.30 Mn |
| Jun 30, 2025 | 81.20 Mn |
| Mar 31, 2025 | 101.60 Mn |
| Dec 31, 2024 | 118.50 Mn |
| Sep 30, 2024 | 105.30 Mn |
| Jun 30, 2024 | 126.20 Mn |
| Mar 31, 2024 | 92.80 Mn |
| Dec 31, 2023 | 108.60 Mn |
| Sep 30, 2023 | 107.50 Mn |
| Jun 30, 2023 | 114.30 Mn |
| Dec 31, 2022 | 112.00 Mn |